The Consiglio Nazionale delle Ricerche and the Societa Industria Farmaceutica Italiana SpA (SIFI) have described new peptides acting as vascular endothelial growth factor receptor 1 (VEGFR-1; FLT1) and VEGFR-2 inhibitors reported to be useful for the treatment of cancer, choroidal neovascularization, hematopoiesis disorders, macular edema, central retinal vein occlusion, central serous retinopathy, diabetic retinopathy and wet macular degeneration, among other disorders.